Melatonin in Musculoskeletal and Spine-Related Conditions: A Systematic Review of Preclinical and Clinical Evidence.
- 1Orthopedics and Traumatology Department, Medical School, University of Perugia, S. Maria della Misericordia Hospital, 06123 Perugia, Italy.
- 2Anaesthesia and Resuscitation, Department of Medicine and Surgery, S. Maria Misericordia Hospital, S. Andrea delle Fratte, 06132 Perugia, Italy.
- 3Division of Clinic Anaesthesia, Department of Emergency Hospital Riuniti, Conca Street 71, 60126 Ancona, Italy.
Abstract
Background and Objectives: Experimental studies suggest that melatonin can influence antioxidant, inflammatory, mitochondrial, and chronobiological pathways relevant to musculoskeletal degeneration, repair, and selected spine-related conditions, but clinical translation remains uncertain. This systematic review evaluated primary in vitro, animal, and human evidence concerning exogenous parent melatonin in these conditions. Materials and Methods: PubMed/MEDLINE and Europe PMC were searched from inception to 6 August 2026; ClinicalTrials.gov was mapped separately. Eligible reports were peer-reviewed comparative primary investigations. One reviewer performed screening, extraction, and a screen-level methodological limitation assessment, followed by a complete consistency pass; no automation tools were used. Complete articles were consulted where accessible, but access status was not logged prospectively and the exact number accessed cannot be reconstructed reliably. Because quantitative pooling was not appropriate, evidence was synthesized by stream and clinical domain according to PRISMA 2020 and SWiM. The review was not registered, and no standalone protocol was prepared. Results: The searches yielded 3201 records and 1646 unique records after deduplication. Of 437 reports taken forward for retrieval and report-level assessment using available information, 208 were included (23 in vitro, 142 animal, and 43 human reports). Preclinical studies generally reported osteogenic, chondroprotective, antioxidant, anti-inflammatory, mitochondrial, and tissue-repair effects, but findings were not uniformly favorable: high-dose fracture-remodeling impairment and MT2-dependent heterotopic ossification were reported. Human evidence was limited, heterogeneous, and showed frequent screen-level methodological limitations. Formulations, routes, and exposures were non-equivalent. Conclusions: Melatonin is biologically plausible but clinically unproven in the reviewed conditions. No formulation, dose, or route can presently be recommended for disease modification, neurological recovery, or tissue regeneration.
Related
- Melatonin and Female Fertility: A Systematic Review and Meta-Analysis of Clinical Supplementation, In Vitro Experiments, and Observational Evidence
- CD47–SIRPα as a Therapeutic Target in Sarcoma: A Systematic Review of Expression, Preclinical, and Clinical Evidence
- Clinical translation of artificial intelligence in musculoskeletal care: a systematic review of current applications, evidence gaps, and implementation readiness
- Moxibustion and the gut microbiota-inflammation axis: a systematic review and meta-analysis of clinical and preclinical studies.
- Circadian rhythm and cancer-related pain: a systematic review of preclinical and clinical evidence
BibTeX
@article{bisaccia2026melatonin,
title = {{Melatonin in Musculoskeletal and Spine-Related Conditions: A Systematic Review of Preclinical and Clinical Evidence.}},
author = {Michele Bisaccia and Barbara Bifarini and Umberto Ripani and Lorenzo Lucchetta and Edoardo Bonanno and Marco Siragusano and Dario Di Mitri and Francesco Bronzini and Giuseppe Rinonapoli},
journal = {Medicina (Kaunas, Lithuania)},
year = {2026},
month = oct,
doi = {10.3390/medicina62101946},
url = {https://europepmc.org/article/MED/42942477},
note = {CC BY},
}
RIS
TY - JOUR
TI - Melatonin in Musculoskeletal and Spine-Related Conditions: A Systematic Review of Preclinical and Clinical Evidence.
AU - Michele Bisaccia
AU - Barbara Bifarini
AU - Umberto Ripani
AU - Lorenzo Lucchetta
AU - Edoardo Bonanno
AU - Marco Siragusano
AU - Dario Di Mitri
AU - Francesco Bronzini
AU - Giuseppe Rinonapoli
PY - 2026
DA - 2026/10/09
JO - Medicina (Kaunas, Lithuania)
DO - 10.3390/medicina62101946
UR - https://europepmc.org/article/MED/42942477
AB - Background and Objectives: Experimental studies suggest that melatonin can influence antioxidant, inflammatory, mitochondrial, and chronobiological pathways relevant to musculoskeletal degeneration, repair, and selected spine-related conditions, but clinical translation remains uncertain. This systematic review evaluated primary in vitro, animal, and human evidence concerning exogenous parent melatonin in these conditions. Materials and Methods: PubMed/MEDLINE and Europe PMC were searched from inception to 6 August 2026; ClinicalTrials.gov was mapped separately. Eligible reports were peer-reviewed comparative primary investigations. One reviewer performed screening, extraction, and a screen-level methodological limitation assessment, followed by a complete consistency pass; no automation tools were used. Complete articles were consulted where accessible, but access status was not logged prospectively and the exact number accessed cannot be reconstructed reliably. Because quantitative pooling was not appropriate, evidence was synthesized by stream and clinical domain according to PRISMA 2020 and SWiM. The review was not registered, and no standalone protocol was prepared. Results: The searches yielded 3201 records and 1646 unique records after deduplication. Of 437 reports taken forward for retrieval and report-level assessment using available information, 208 were included (23 in vitro, 142 animal, and 43 human reports). Preclinical studies generally reported osteogenic, chondroprotective, antioxidant, anti-inflammatory, mitochondrial, and tissue-repair effects, but findings were not uniformly favorable: high-dose fracture-remodeling impairment and MT2-dependent heterotopic ossification were reported. Human evidence was limited, heterogeneous, and showed frequent screen-level methodological limitations. Formulations, routes, and exposures were non-equivalent. Conclusions: Melatonin is biologically plausible but clinically unproven in the reviewed conditions. No formulation, dose, or route can presently be recommended for disease modification, neurological recovery, or tissue regeneration.
SN - 1010-660X
SN - 1648-9144
ER -